Catechol-O-Methyltransferase inhibitors in preclinical models as adjuncts of l-Dopa treatment

International Review of Neurobiology

Volumn 95, Issue C, 2010, Pages 191-205

  Marin, Concepció ^a,c   Obeso, J A ^b,c  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Animal model; CDS; COMT; COMT inhibition; Dyskinesia; Entacapone; L dopa; Motor fluctuations

Indexed keywords

CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; LEVODOPA; MESSENGER RNA; PREPRODYNORPHIN; PREPROENKEPHALIN;

BASAL GANGLION; BOOK; CHRONIC DRUG ADMINISTRATION; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; LOW DRUG DOSE; MOTOR ACTIVITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 78649344814     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-381326-8.00008-9     Document Type: Chapter

References (80)

1. Andersson M., Hilbertson A., Cenci M.A. Striatal FosB expression is causally linked with L-dopa-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 1999, 6:461-474.
2. Arbuthnott G.W., Ungerstedt U. Turning behavior induced by electrical stimulation of the nigro-neostriatal system of the rat. Exp. Neurol. 1975, 47:162-172.
3. Aubert I., Guigoni C., Hakansson K., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 2005, 57:17-26.
4. Bédard P.J., DiPaolo T., Falardeu P., Boucher R. Chronic treatment with levodopa, but not bromocriptine induces dyskinesia in MPTP-treated parkinsonian monkeys. Correlation with [3H]-spiperone binding. Brain Res. 1986, 379:294-299.
5. Bezard E., Brotchie J.M., Gross C.E. Pathophysiology of levodopa-induced dyskinesia. Potential for new therapies. Nat. Rev. Neurosci. 2001, 2:577-588.
6. Blanchet P.J., Calon F., Martel J.C., et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U91356A) in MPTP-exposed monkeys. J. Pharmacol. Exp. Ther. 1995, 272:854-859.
7. Boraud T., Bezard E., Bioulac B., Gross C.E. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurons in the MPTP-treated monkey. Brain 2001, 124:546-557.
8. Bychkov E., Ahmed M.R., Dalby K.N., Gurevich E.V. Dopamine depletion and subsequent treatment with L-dopa, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J. Neurochem. 2007, 102:699-711.
9. Cenci M.A., Lee C.S., Björklund A. L-dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin-and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
10. Cenci M.A., Ohlin K.E. Rodent models of treatment-induced motor complications in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15(Suppl. 4):S13-S17.
11. Chase T.N. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998, 50(5 Suppl. 5):S17-S25.
12. Chase T.N., Baronti F., Fabbrini G., Heuser I.J., Juncos J.L., Mouradian M.M. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 1989, 39(Suppl. 2):7-10.
13. Doucet J.P., Nakabeppu Y., Bedard P.J., et al. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur. J. Neurosci. 1996, 8:365-381.
14. Engber T.M., Papa S.M., Boldry R.C., Chase T.N. NMDA receptor blockade reverses motor response alterations induced by levodopa. NeuroReport 1994, 5:2586-2588.
15. Fox S.H., Lang A.E. Levodopa-related motor complications-phenomenology. Mov. Dis. 2008, 23(Suppl. 3):S509-S514.
16. Gardoni F., Picconi B., Ghiglieri V.P., et al. A critical interaction between NR2B. and MAGUK in L-dopa-induced dyskinesia. J. Neurosci. 2006, 26:2914-2922.
17. Gerlach M., van de Buuse M., Blaha C., Bremen D., Riederer P. Entacapone increases and prolongs the central effects of L-dopa in the 6-hydroxydopamine-lesioned rat. Naunyn Schmiedebergs Arch. Pharmacol. 2004, 370:388-394.
18. Heikkinen H., Varhe A., Laine T., et al. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa. Br. J. Clin. Pharmacol. 2002, 54:363-371.
19. Henry B., Crossman A.R., Brotchie J.M. Effect of repeated L-dopa, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 1999, 155:204-220.
20. Jenner P. Avoidance of dyskinesia. Preclinical evidence for continuous dopaminergic stimulation. Neurology 2004, 62(Suppl. 1):S47-S55.
21. Jenner P. From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease. Parkinsonism Relat. Disord. 2009, 15(Suppl. 4):S18-S23.
22. Jiménez A., Marin C., Bonastre M., Tolosa E. Narrow beneficial effect of dextromethorphan on levodopa-induced motor response alterations in an experimental model of parkinsonism. Brain Res. 1999, 839:190-193.
23. Juncos J.L., Engber T.M., Raisman R., Susel Z., Thibaut F., Ploska A., Agid Y., Chase T.N. Continuous and intermittent levodopa differentially affect basal ganglia function. Ann. Neurol. 1989, 25:473-478.
24. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur. J. Neurosci. 2002, 15:120-132.
25. Luquin M.R., Scipione O., Vaamonde J., Gershanik O., Obeso J.A. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov. Dis. 1992, 7:117-124.
26. Maratos E.C., Jackson M.J., Pearce R.K., Cannizzaro C., Jenner P. Both short-and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-dopa in the MPTP-lesioned common marmoset (Callithrix jacchus. Exp. Neurol. 2003, 179:90-102.
27. Marconi R., Lefebvre-Caparros D., Bonnet A.M., Vidailhet M., Dubois B., Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov. Dis. 1994, 9:2-12.
28. Marin C., Aguilar E., Bonastre M., Tolosa E., Obeso J.A. Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats. Exp. Neurol. 2005, 192:184-193.
29. Marin C., Aguilar E., Mengod G., Cortés R., Obeso J.A. Concomitant short-and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study. Eur. J. Neurosci. 2007, 25:259-269.
30. Marin C., Aguilar E., Mengod G., Cortés R., Obeso J.A. Effects of early vs late initiation of levodopa treatment in hemiparkinsonian rats. Eur. J. Neurosci. 2009, 30:823-832.
31. Marin C., Aguilar E., Mengod G., Cortés R., Rodríguez-Oroz M.C., Obeso J.A. Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes. Neurobiol. Dis. 2008, 32:340-348.
32. Marin C., Aguilar E., Obeso J.A. Coadminsitration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats. Mov. Dis. 2006, 21:646-653.
33. Marin C., Jiménez A., Bonastre M., Chase T.N., Tolosa E. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in parkinsonian rats. Synapse 2000, 36:267-274.
34. Marin C., Jiménez A., Vila M., Bonastre M., Hirsch E.C., Agid Y., Tolosa E. LY293558, an AMPA glutamate receptor antagonist prevents and reverses levodopa-induced motor fluctuations in parkinsonian rats. Synapse 2001, 42:40-47.
35. Marin C., Papa S., Engber T.M., Bonastre M., Tolosa E., Chase T.N. MK801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res. 1996, 736:202-205.
36. Marin C., Rodríguez-Oroz M.C., Obeso J.A. Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?. Exp. Neurol. 2006, 197:269-274.
37. Marsden C.D. Problems with long-term levodopa therapy for Parkinson's disease. Clin. Neuropharmacol. 1994, 17(Suppl. 2):S32-S44.
38. Marsden C.D., Parkes J.D. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976, 1(7954):292-295.
39. Miller J.W., Shukitt-Hale B., Villalobos-Molina R., Nadeu M., Selhub J., Joseph J.A. Effect of L-dopa and the catechol-O-methyltrasnferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin. Neuropharmacol. 1997, 20:55-66.
40. Morissette M., Goulet M., Soghomonian J.J., Blanchet P.J., Calon F., Bédard P.J., Di Paolo T. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-dopa therapy. Brain Res. Mol. Brain Res. 1997, 49:55-62.
41. Morissette M., Grondin R., Goulet M., Bédard P.J., Di Paolo T. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J. Neurochem. 1999, 72:682-692.
42. Mouradian M.M., Heuser I.J.E., Baronti F., Chase T.N. Modification of central acting dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann. Neurol. 1990, 27:18-23.
43. Muenter M.D., Tyce G.M. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response and side effects. Mayo Clin. Proc. 1971, 46:231-239.
44. Müller T., Erdmann C., Muhlack S., Bremen D., Przuntek H., Woltalla D. Entacapone improves complex movement performance in patients with Parkinson's disease. J. Clin. Neurosci. 2007, 14:424-428.
45. Nissinen E., Lindén I.B., Schultz E., Pohto P. Biochemical and pharmacologcial properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedeberg Arch. Pharmacol. 1992, 346:262-266.
46. Nutt J.G. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990, 40:340-345.
47. Nutt J.G., Carter J.H. Apomorphine can sustain the long-duration response to L-dopa in fluctuating PD. Neurology 2000, 54:247-250.
48. Nutt J.G., Carter J.H., Woodward W.R. Long-duration response to levodopa. Neurology 1995, 45:1613-1616.
49. Nutt J.G., Woodward W.R., Beckner R.M., Stone C.K., Berggren K., Carter J.H., Gancher S.T., Hammerstad J.P. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994, 44:913-919.
50. Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13(Suppl.):S13-S17.
51. Obeso J.A., Grandas F., Herrero M.T., Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur. J. Neurosci. 1994, 6:889-897.
52. Obeso J.A., Luquin M.R., Martinez-Lage M. Intravenous lisuride corrects motor oscilations in Parkinson's disease. Ann. Neurol. 1986, 19:31-35.
53. Obeso J.A., Rodríguez-Oroz M.C., Chana P., Lera G., Rodríguez M., Olanow C.W. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000, 55(11 Suppl. 4):S13-S20.
54. Olanow C.W., Agid Y., Mizuno Y., et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov. Dis. 2004, 19:997-1005.
55. Olanow C.E., Obeso J.A. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease. Implications for the use of COMT inhibitors. Neurology 2000, 55:S72-S77.
56. Olanow C.W., Obeso J.A., Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006, 5:677-687.
57. Paija O., Laine K., Kultalahti E.R., Leinonen M., Huupponen R., Gordin A., Reinikainen K. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. Clin. Neuropharmacol. 2005, 28:115-119.
58. Papa S.M., Desimone R., Fiorani M., Oldfield E.H. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann. Neurol. 1999, 46:732-738.
59. Papa S.M., Engber T.M., Kask A.M., Chase T.N. Motor fluctuations in levodopa-treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res. 1994, 662:69-74.
60. Pearce R.K.B., Banerji T., Jenner P., Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than levodopa in MPTP-treated marmoset. Mov. Dis. 1998, 13:234-241.
61. Piccini P., Brooks D.J., Korpela K., Pavese N., Karlsson M., Gordin A. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J. Neurol. Neurosurg. Pscyhiatr. 2000, 68:589-594.
62. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in L-dopa-induced dyskinesia. Nat. Neurosci. 2003, 6:501-506.
63. Quattrone A., Zappia M., Aguglia U., et al. The subacute levodopa test for evaluating long-duration response in Parkinson's disease. Ann. Neurol. 1995, 38:389-395.
64. Quinn N., Parkes J.D., Marsden C.D. Control of on/off phenomena by continuous intravenous infusion of levodopa. Neurology 1984, 34:1131-1136.
65. Ravenscroft P., Chalon S., Brotchie J.M., Crossman A.R. Ropinirole versus L-dopa effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Exp. Neurol. 2004, 185:36-46.
66. Ruottinen H.M., Rinne U.K. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin. Neuropharmacol. 1996, 19:283-296.
67. Schapira A.H., Bezard E., Brotchie J. Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug Discov. 2006, 5:845-854.
68. Schapira A.H.V., Emre M., Jenner P., Poewe W. Levodopa in the treatment of Parkinson's disease. Eur. J. Neurol. 2009, 16:982-989.
69. Silverman P.B. On-off effects of dopamine receptor agonists in the hemi-parkinsonian rats. Eur. J. Pharmacol. 1993, 242:31-36.
70. Smith L.A., Gordin A., Jenner P., Marsden C.D. Entacapone enhances levodopa-induced reversal of motor disability in MPTP-treated common marmosets. Mov. Dis. 1997, 12:935-945.
71. Smith L.A., Jackson M.J., Al-Barghouthy G., Rose S., Kuoppamaki M., Olanow W., Jenner P. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov. Dis. 2005, 20:306-314.
72. Stocchi F., Barbato L., Nordera G., Bolner A., Caraceni T. Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients. J. Neural Transm. 2004, 111:173-180.
73. Stocchi F., Olanow C.W. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 2004, 62(1 Suppl. 1):S56-S63.
74. Stocchi F., Rascol O., Poewe W., Jankovic J., Tolosa E., Barone P., Lang A.E., Kieburtz K., Olanow C.W. Initiating Levodopa/Carbidopa therapy with and without entacapone in early Parkinson Disease: The STRIDE-PD study. Ann. Neurol. 2010, 68:18-27.
75. Stockwell K.A., Scheller D.K., Smith L.A., Rose S., Iravani M.M., Jackson M.J., Jenner P. Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-dopa in MPTP-treated common marmosets. Exp. Neurol. 2010, 22:79-85.
76. Stockwell K.A., Virley D.J., Perren M., Iravani M.M., Jackson M.J., Rose S., Jenner P. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets. Exp. Neurol. 2008, 211:172-179.
77. Tamim M.K., Samadi P., Morissette M., Grégoire L., Ouattara B., Lévesque D., Rouillard C., Di Paolo T. Effect of non-dopaminergic drug treatment on levodopa-induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides. Neuropharmacology 2010, 558:286-296.
78. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxydopamine lesions of the nigrostriatal dopamine system. Brain Res. 1970, 24:485-493.
79. Winkler C., Kirik D., Björklund A., Cenci M.A. L-dopa-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol. Dis. 2002, 10:165-186.
80. Zubair M., Jackson M.J., Tayarani-Binazir K., Stockwell K.A., Smith L.A., Rose S., Olanow W., Jenner P. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates. Exp. Neurol. 2007, 208:177-184.